Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
The test, called Immunoscore, is designed to predict the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites.
As part of the deal, Atara will receive $60 million upfront and be eligible for up to $610 million in milestone payments, as well as tiered royalties based on net sales.
Artios can receive $30 million in up-front and near-term payments, and up to $860 million per target if Merck KGaA exercises its exclusive development rights.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The Swedish company will use the funds to grow its pipeline of antibodies to treat metastatic cancer and other diseases with the help of its Abiprot platform.
